MannKind Corporation has extended its collaboration with Thirona Bio to continue work toward an inhaled therapy for fibrotic diseases affecting the lungs, including idiopathic pulmonary fibrosis (IPF). Under a collaboration established last year, the companies are evaluating the therapeutic potential of FBM5712, an investigational medicine designed to…
MannKind, Thirona Bio Extending Joint Work on Inhalable PF Therapy
If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…
I thought I understood the role of a caregiver. It was based on what I learned and observed watching others. It turns out I did not fully appreciate the role until I had a caregiver. The role of the caregiver is not a single responsibility, but a collection of…
Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…
Pulmonary Fibrosis News brought you daily coverage throughout 2021 of the latest scientific findings, treatment developments, and clinical trials related to pulmonary fibrosis (PF). As a reminder of what mattered most to you during the past year, here are the top 10 most-read articles of 2021, with a brief…
I have tried countless times to describe idiopathic pulmonary fibrosis (IPF). In 2019, I tried to explain what it physically feels like, but I still can’t find words that adequately convey how hard living with IPF is, especially as it progresses. I never do the experience justice. Since most…
Idiopathic pulmonary fibrosis (IPF) patients with increased formation of type VI collagen — a major extracellular matrix (ECM) molecule involved in wound healing and scarring — are at higher risk of having progressive disease, a real-world study shows. Also, type VI collagen breakdown tended to increase in patients with progressive…
The glam and glitzy affair that is Broadway Belts for PFF! is set for March 7 in New York City. And for the first time, supporters can experience the event interactively from home. The 12th annual event — the single largest fundraiser for the Pulmonary Fibrosis Foundation (PFF) —…
The weight of the world is getting heavier. With the holiday season underway and the omicron variant of the coronavirus spreading, feelings of anxiety, sadness, and fear of social isolation are increasing. While I acknowledge that predictions are not always accurate, current scientific models suggest that this variant…
The University of Calgary is developing a clinical tool to help identify the environmental and occupational risks of pulmonary fibrosis (PF), an undertaking that could lead to a deeper understanding of how the disease takes hold and aid in developing treatments. During the 18-month project, supported by the Three…
